BridgeBio Pharma Files 2025 Proxy Statement
Ticker: BBIO · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
BridgeBio Proxy filed - vote on directors & pay coming up June 20.
AI Summary
BridgeBio Pharma, Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for its annual meeting on June 20, 2025. The filing outlines the company's governance and proposals for shareholders, including the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership and voting matters, impacting their ability to influence corporate decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures beyond standard corporate governance information.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- 0001140361-25-016452 (filing_id) — Accession Number
- 20250430 (date) — Filing Date
- 20250620 (date) — Period of Report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When is the period of report for this filing?
The period of report for this filing is June 20, 2025.
What is the filing date of this document?
The filing date of this document is April 30, 2025.
What is the company's SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding BridgeBio Pharma, Inc. (BBIO).